<DOC>
	<DOC>NCT00753480</DOC>
	<brief_summary>This is a Phase I, multicenter, open-label, dose-escalation study of single-agent D4064A administered by IV infusion to patients with recurrent or persistent epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), and fallopian tube cancer (FTC) who have previously received a platinum-containing regimen. The study will enroll up to 56 patients at up to six investigative sites in the United States.</brief_summary>
	<brief_title>A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<criteria>ECOG performance status of 0 or 1 Advanced, histologically documented epithelial ovarian, primary peritoneal, or fallopian tube cancer that has progressed or relapsed during or within 12 months of treatment with a platinumcontaining chemotherapy regimen, and for which no standard therapy exists History of receiving five or fewer prior chemotherapycontaining regimens for EOC, PPC, or FTC (including primary therapy) Prior treatment with chemotherapy or experimental anticancer agents within 4 weeks prior to Day 1 Prior treatment with oregovomab (OvaRex(R)) or abagovomab History or clinical evidence of central nervous system or brain metastases Grade â‰¥ 2 peripheral neuropathy History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies History of clinically symptomatic liver disease, including viral or other hepatitis, history of or current alcoholism, or cirrhosis Untreated or persistent/recurrent malignancy (other than EOC, PPC, or FTC)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>EOC</keyword>
	<keyword>PPC</keyword>
	<keyword>FTC</keyword>
</DOC>